More on OTLK
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.52 |
|
|||
| Open | $0.51 | ||||
| 52 Wk High | $0.03 | ||||
| 52 Wk Low | $0.01 | ||||
| Day High | $0.53 | ||||
| Day Low | $0.49 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,529,538 | ||||
- Form SCHEDULE 13G Outlook Therapeutics, Filed by: Empery Asset Management, LP
- Outlook Therapeutics names Greg DiPasquale as CCO ahead of U.S. launch
- Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
- Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
- Outlook Therapeutics files for permanent J-code for Lytenava with CMS
- Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
- Form 8-K Outlook Therapeutics, For: Sep 25
- Form 8-K Outlook Therapeutics, For: Sep 16
- Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
- Outlook Therapeutics CEO discusses Lytenava FDA approval and U.S. launch
Entities mentioned with OTLK
- FDA | View Related Stories »
- PDUFA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- H.C. Wainwright | View Related Stories »
- S3 | View Related Stories »
- Earnings | View Related Stories »
- Show More...
